These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7614775)

  • 21. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
    Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ
    Int J STD AIDS; 1995; 6(1):19-26. PubMed ID: 7727578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination 3TC/AZT therapy shows promise.
    AIDS Clin Care; 1995 Mar; 7(3):22. PubMed ID: 11362192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children.
    Chadwick EG; Nazareno LA; Nieuwenhuis TJ; Massarella JW; de Dennis SR; Williams K; Yogev R
    J Infect Dis; 1995 Dec; 172(6):1475-9. PubMed ID: 7594705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A kinder, gentler ddC... for $7,200 a year.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dideoxycytidine: current clinical experience and future prospects. A summary.
    Broder S; Yarchoan R
    Am J Med; 1990 May; 88(5B):31S-33S. PubMed ID: 2159708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
    Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
    Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
    Kaulen P; Pham DT; Baranowski E; Wollensak J
    Ger J Ophthalmol; 1993 Nov; 2(6):412-5. PubMed ID: 8312826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New combo trial/same old style.
    Gilden D
    GMHC Treat Issues; 1995 Apr; 9(4):9. PubMed ID: 11362369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
    Bruisten SM; Reiss P; Loeliger AE; van Swieten P; Schuurman R; Boucher CA; Weverling GJ; Huisman JG
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1053-8. PubMed ID: 9718120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
    Scott-Lennox JA; Mills RJ; Burt MS
    Ann Pharmacother; 1998 May; 32(5):525-30. PubMed ID: 9606471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major study shows AZT monotherapy inferior.
    James JS
    AIDS Treat News; 1995 Sep; (no 231):3-4. PubMed ID: 11362867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
    Stretcher BN
    Clin Pharmacokinet; 1995 Jul; 29(1):46-65. PubMed ID: 7586898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
    van Leeuwen R; Lange JM; Hussey EK; Donn KH; Hall ST; Harker AJ; Jonker P; Danner SA
    AIDS; 1992 Dec; 6(12):1471-5. PubMed ID: 1283519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine (3TC) approved for combination use with AZT.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.